Sanofi India Ltd
SANOFISanofi India Ltd's stock has fallen further than its earnings. EPS fell 21.0% in a year while the price moved −39.2%.
The sharpest disagreement: Domestic institutions moved −2.7 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced.
The price is in a downtrend (57 weeks in) while the P/E sits at the 35th percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +20.0% year on year, and 84% of the last 3 years' profit arrived as cash. What settles it: whether the register turns back in the story’s favour.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Sanofi India Ltd trades at ₹3,079, in a downtrend and 57 weeks into that stage. That is −16.7% against its own 200-day average. It sits at 0% of a 52-week range of ₹3,079 to ₹4,781. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (3 weeks and counting).
Today the stock is in a downtrend — week 57 of stage 4, confirmed. At ₹3,079 it trades −16.7% versus its 200-day average and sits at 0% of its 52-week range (₹3,079–₹4,781).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +14% while the NIFTY 500 moved +267% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (3 weeks and counting; last ahead the week of 2026-08-21) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Sanofi India Ltd trades at 20.7× P/E, near the bottom of its own range — cheaper only 35% of the time. Its long-run median P/E is 22.0×, measured across 10.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 20.7× is near the bottom of its own range — cheaper only 35% of the time, against a long-run median of 22.0× measured over 10.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −21.0% against a −39.2% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the −9.4%/yr price move, ~−9.9%/yr came from earnings growth and ~+0.5 pp from the multiple (roughly flat); over 10y, of the +1.4%/yr price move, ~+0.9%/yr came from earnings growth and ~+0.5 pp from the multiple (roughly flat). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 45% on reported income across 11 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Sanofi India Ltd reads as improving on its fundamental arc. Improving — profit growth bottomed 6 quarters ago at −34.1% and has held its recovery at +20.0% (single-quarter readings), ROCE lifting at 58.0%. The read is built from 9 quarters across 3 curves, on partial evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −8.7% | −12.8% | −8.7% | −1.8% |
| Profit | −21.0% | −19.2% | −7.3% | +0.2% |
| EPS | −21.0% | −19.3% | −7.3% | +0.2% |
| Share price | −39.2% | −11.1% | −9.4% | +1.4% |
4-Factor Sector Score
46.0/100 — rank 7 of 8 in Pharma - MNC bulk Drugs · 82% evidence confidence
Sanofi India Ltd scores 46.0 out of 100 against the 8 companies it is compared with in Pharma - MNC bulk Drugs, ranking 7. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 15.8 + 15.8 + 10.1 + 4.3 = 46. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Sanofi India Ltd reported ₹438 Cr of revenue in the Jun 26 quarter, +7.9% year on year. Over 10 years it has compounded at −1.8% a year. The last full year, FY25, came in at ₹1,837 Cr. The last four reported quarters add to ₹1,805 Cr.
FY25 revenue came in at ₹1,837 Cr (−8.7% on the year), capping 10 years at −1.8% compound. The latest quarter (Jun 26) printed ₹438 Cr, +7.9% year on year.
Pace check: the last four quarters averaged −7.9% growth against the decade's −1.8% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −8.9% over the last 4 quarters against −3.4%/yr over the last 8 — rolling over; TTM profit −10.5% vs −21.7%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Sanofi India Ltd's operating margin is 26.0% in the Jun 26 quarter, +3.0 percentage points against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged 17.0% to 28.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 26.0%, +3.0 pp against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged 17.0%–28.0%.
Why the margin moved: operating margin went +3.0 pp year on year while gross margin went −0.1 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Sanofi India Ltd earned ₹84.0 Cr of net profit in the Jun 26 quarter, +20.0% year on year. Full-year FY25 profit was ₹327 Cr. The 10-year compound rate is 0.2%. That is 19.2% of the quarter's revenue. The same quarter a year earlier earned ₹70.0 Cr.
Jun 26 profit was ₹84.0 Cr, +20.0% year on year. On the full year, FY25 printed ₹327 Cr (−21.0%), and the 10-year compound rate is 0.2%.
Why profit moved: revenue contributed +7.9% and the margin +3.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit −8.3% vs revenue −7.9%. Profit and revenue are moving roughly in step.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 84% of Sanofi India Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was ₹438 Cr of operating cash against ₹327 Cr of profit. After ₹23.0 Cr of capital spending, ₹415 Cr was left as free cash.
FY25: operating cash of ₹438 Cr against reported profit of ₹327 Cr, leaving free cash of ₹415 Cr after ₹23.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 84% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 84%: the cash cycle stretched 50 days between FY20 and FY25 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Sanofi India Ltd's cash conversion cycle runs 83 days in FY25, up from 33 days in FY20. Capital spending ran ₹100 Cr over the last 3 years. At FY25 sales of ₹1,837 Cr each day of that cycle holds about ₹5.0 Cr, so roughly ₹418 Cr sits inside the business at any moment.
FY25: debtors at 35 days, inventory at 127 days — roughly 4.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 83 days, looser than FY20's 33.
The full loop: cash goes out to suppliers and production on day 0; stock waits 127 days to sell; customers pay about 35 days after that; and suppliers themselves are paid at 79 days — netting out to the 83-day cycle.
In money terms: at FY25 sales of ₹1,837 Cr, each day of the cycle holds about ₹5.0 Cr — so the 83-day loop keeps roughly ₹418 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹100 Cr over the last 3 fiscal years against ₹114 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹12.0 Cr (FY25) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Sanofi India Ltd earns a ROCE of 58% in FY25. That is up from a trough of 22% in FY14. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 17.8% net margin on 1.46× asset turns.
FY25 ROCE is 58%, recovered from a FY14 trough of 22% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 17.8% net margin × 1.46× asset turns × 1.68× balance-sheet leverage ≈ 43.7% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 45% on reported income across 11 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Sanofi India Ltd carries ₹18.0 Cr of borrowings against ₹749 Cr of equity in FY25, a debt-to-equity of 0.02. Operating profit covers the interest bill north of 100×. Over 5 years borrowings went from ₹23.0 Cr to ₹18.0 Cr. Capital spending ran ₹100 Cr across the last 3 of those years.
FY25: borrowings of ₹18.0 Cr against equity of ₹749 Cr — a debt-to-equity of 0.02. Operating profit covers the interest bill north of 100×. Over 5 years borrowings went from ₹23.0 Cr to ₹18.0 Cr while capital spending ran ₹100 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 45% on reported income across 11 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions cut 2.7 points of Sanofi India Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 19.9% of the company. Foreign institutions moved −0.1 points over the same window, to 5.7%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: −2.7 points over 8 quarters to 19.9%; Foreign institutions: −0.1 points over 8 quarters to 5.7%; Promoters: +0.0 points over 8 quarters to 60.4%.
🚨 Why the register moved: domestic institutions drove it (−2.7 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Sanofi India Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Procter & Gamble Health LtdPGHL | 65.6/100Favorable setup94% evidence | ASLEEP | 25.1/35 Revenue 12.6% · PAT 19.3% · OPM change 0 pp 100% evidence | 18.4/25 ROCE 83.9% · OPM 27% 100% evidence | 13.3/20 P/E 27× · PEG 1.23 100% evidence | 8.8/20 RS sector -2.5% · RS bench -4% · 1Y -16.3%7 of 11 weeks ahead 70% evidence |
| Exact sum: 25.1 + 18.4 + 13.3 + 8.8 = 65.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Sanofi Consumer Healthcare India LtdSANOFICONR | 62.4/100Mixed-positive evidence67% evidence | BASING | 28.6/35 Revenue 31% · PAT 33% · OPM change 6 pp 71% evidence | 20.9/25 ROCE 89.9% · OPM 38% 76% evidence | 9.8/20 P/E 34.8× · PEG — 15% evidence | 3.1/20 RS sector -15.5% · RS bench -10.4% · 1Y -22.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 28.6 + 20.9 + 9.8 + 3.1 = 62.4 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -15.5% and the one-year return is -22.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 3Pfizer LtdPFIZER | 56.2/100Mixed-positive evidence100% evidence | ASLEEP | 19.5/35 Revenue 10.6% · PAT -9.2% · OPM change 3 pp 100% evidence | 14.5/25 ROCE 24.1% · OPM 38% 100% evidence | 19.5/20 P/E 24.2× · PEG 0.73 100% evidence | 2.7/20 RS sector -20.1% · RS bench -15.1% · 1Y -20.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 14.5 + 19.5 + 2.7 = 56.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Glaxosmithkline Pharmaceuticals LtdGLAXO | 54.7/100Mixed-positive evidence100% evidence | BREAKING OUT | 13.3/35 Revenue 5.8% · PAT 12.4% · OPM change 0 pp 100% evidence | 18.0/25 ROCE 61.4% · OPM 31% 100% evidence | 5.7/20 P/E 45.5× · PEG 4.12 100% evidence | 17.7/20 RS sector 7% · RS bench 13.7% · 1Y 2.1%6 of 12 weeks ahead 100% evidence |
| Exact sum: 13.3 + 18 + 5.7 + 17.7 = 54.7 · Decision use: Price leads the evidence: RS versus the benchmark is 13.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 5Abbott India LtdABBOTINDIA | 52.9/100Mixed-positive evidence94% evidence | BASING | 18.7/35 Revenue 6.3% · PAT 11.2% · OPM change 3 pp 100% evidence | 15.4/25 ROCE 44.8% · OPM 29% 100% evidence | 9.3/20 P/E 33.6× · PEG 3.6 100% evidence | 9.5/20 RS sector -0.7% · RS bench -6.1% · 1Y -18%3 of 10 weeks ahead 70% evidence |
| Exact sum: 18.7 + 15.4 + 9.3 + 9.5 = 52.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Novartis India LtdNOVARTIND | 47.7/100Mixed-negative evidence100% evidence | TURNING | 14.1/35 Revenue 5.4% · PAT -4.9% · OPM change 3 pp 100% evidence | 7.8/25 ROCE 16.3% · OPM 34% 100% evidence | 5.8/20 P/E 60.4× · PEG 1.96 100% evidence | 20.0/20 RS sector 107.8% · RS bench 118.6% · 1Y 156.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 7.8 + 5.8 + 20 = 47.7 · Decision use: Price leads the evidence: RS versus the benchmark is 118.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 7Sanofi India Ltdthis pageSANOFI | 46.0/100Mixed-negative evidence82% evidence | BASING | 15.8/35 Revenue -8.9% · PAT -10.5% · OPM change 3 pp 95% evidence | 15.8/25 ROCE 57.5% · OPM 26% 76% evidence | 10.1/20 P/E 20.7× · PEG — 50% evidence | 4.3/20 RS sector -23% · RS bench -18% · 1Y -39.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.8 + 15.8 + 10.1 + 4.3 = 46 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Astrazeneca Pharma India LtdASTRAZEN | 31.7/100Adverse evidence87% evidence | ASLEEP | 9.8/35 Revenue 31.2% · PAT -7.1% · OPM change -8 pp 100% evidence | 8.1/25 ROCE 29.3% · OPM 7% 100% evidence | 4.3/20 P/E 97.5× · PEG 3.95 65% evidence | 9.5/20 RS sector 2.3% · RS bench -19.4% · 1Y -25.6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 9.8 + 8.1 + 4.3 + 9.5 = 31.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Sanofi India Ltd's share price today?
Sanofi India Ltd trades at ₹3,079, −39.2% over the past year. The company is valued at ₹7,091 Cr. The stock sits at the very bottom of its 52-week range (₹3,079–₹4,781), −16.7% versus its 200-day average. On the tape, the price is in a downtrend, 57 weeks in. — as of 11 September 2026.
What were Sanofi India Ltd's latest quarterly results?
Sanofi India Ltd reported revenue of ₹438 Cr and net profit of ₹84.0 Cr for the Jun 26 quarter. Revenue rose 7.9% and profit rose 20.0% year on year. Earnings per share were ₹36.30. The operating margin was 26.0%, 3.0 pp higher than a year earlier. — as of 11 September 2026.
What is Sanofi India Ltd's revenue?
Sanofi India Ltd reported revenue of ₹438 Cr in the Jun 26 quarter, +7.9% year on year. For the full FY25 fiscal year, revenue was ₹1,837 Cr (−8.7%). Over the last 10 years revenue compounded at −1.8% a year. — as of 11 September 2026.
What is Sanofi India Ltd's profit?
Sanofi India Ltd earned ₹84.0 Cr of net profit in the Jun 26 quarter, +20.0% year on year. Full-year FY25 profit was ₹327 Cr. The operating margin ran 26.0% in the latest quarter. — as of 11 September 2026.
What is Sanofi India Ltd's market cap?
Sanofi India Ltd's market capitalisation is ₹7,091 Cr at a share price of ₹3,079. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Sanofi India Ltd's P/E ratio?
Sanofi India Ltd trades at a P/E of 20.7×, at the 35th percentile of its own 10-year range, against a long-run median of 22.0×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Sanofi India Ltd pay a dividend?
Yes — Sanofi India Ltd's dividend payout was 87% of profit in FY25, and it recorded a payout in each of its last 12 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Sanofi India Ltd overvalued?
On its own history, Sanofi India Ltd looks cheap: its P/E of 20.7× has been cheaper only 35% of the time in 10 years (long-run median 22.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Sanofi India Ltd growing?
Yes — Sanofi India Ltd is growing: latest-quarter revenue +7.9% year on year, profit +20.0%, and the margin +3.0 pp at 26.0%. The 10-year compound rates are −1.8% (revenue) and 0.2% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Sanofi India Ltd performing?
Sanofi India Ltd is in a downtrend, 57 weeks in. Its latest quarter's revenue rose 7.9% and profit rose 20.0% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Sanofi India Ltd in?
Improving — profit growth bottomed 6 quarters ago at −34.1% and has held its recovery at +20.0% (single-quarter readings), ROCE lifting at 58.0%. The read comes from the last 12 quarters of growth (revenue growth +7.9% latest, profit growth +20.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Sanofi India Ltd in an uptrend?
No — the price is in a downtrend (week 57 of stage 4), trading −16.7% versus its 200-day average and at the very bottom of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Sanofi India Ltd beating the market?
Not lately — on a trailing-13-week view Sanofi India Ltd is currently behind the NIFTY 500 (3 weeks and counting; last ahead the week of 2026-08-21), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +14% against the NIFTY 500's +267% — behind the index over the full window. — as of 11 September 2026.
Will Sanofi India Ltd's share price go up?
This page publishes no price forecast for Sanofi India Ltd. What it measures instead: the share price is ₹3,079, the price is in a downtrend 57 weeks in. Its P/E of 20.7× sits at the 35th percentile of its own 10-year range. — as of 11 September 2026.
Who owns Sanofi India Ltd?
Promoters hold 60.4% of Sanofi India Ltd, foreign institutions 5.7%, domestic institutions 19.9% and the public 14.1% (latest quarter). The biggest move on the register over the last two years: Domestic institutions cut 2.7 points over 8 quarters. — as of 11 September 2026.
Does Sanofi India Ltd have too much debt?
No — Sanofi India Ltd's debt-to-equity is 0.02, and operating profit covers the interest bill north of 100×. FY25 borrowings were ₹18.0 Cr against equity of ₹749 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Sanofi India Ltd's capex?
Sanofi India Ltd spent ₹100 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was ₹23.0 Cr, with ₹12.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Sanofi India Ltd's cash flow?
Sanofi India Ltd generated ₹438 Cr of operating cash flow in FY25 and ₹415 Cr of free cash flow after ₹23.0 Cr of capital spending. Reported profit that year was ₹327 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Sanofi India Ltd's profit real cash?
Yes — over the last 3 fiscal years, 84% of Sanofi India Ltd's reported profit arrived as operating cash. In FY25, operating cash was ₹438 Cr against reported profit of ₹327 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Sanofi India Ltd in its business cycle?
Sanofi India Ltd's FY25 operating margin was 27.0%, against a 12-year band of 17.0%–28.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 26.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What could break the Sanofi India Ltd story?
The sharpest disagreement: Domestic institutions moved −2.7 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Sanofi India Ltd a stock worth studying right now?
This is not investment advice. The machine read: Sanofi India Ltd's stock has fallen further than its earnings. EPS fell 21.0% in a year while the price moved −39.2%. The sharpest open question: whether the register turns back in the story’s favour. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!